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Scavenger receptors constitute a large family of proteins
that are structurally diverse and participate in a wide
range of biological functions. These receptors are ex-
pressed predominantly by myeloid cells and recognize
a variety of ligands, including endogenous and modified
host-derived molecules and microbial pathogens. There
are currently eight classes of scavenger receptors, many
of which have multiple names, leading to inconsistencies
and confusion in the literature. To address this problem,
a workshop was organized by the U.S. National Institute
of Allergy and Infectious Diseases, National Institutes
of Health to help develop a clear definition of scavenger
receptors and a standardized nomenclature based on that
definition. Fifteen experts in the scavenger receptor field
attended the workshop and, after extensive discussion,
reached a consensus regarding the definition of scavenger
receptors and a proposed scavenger receptor nomencla-
ture. Scavenger receptors were defined as cell surface
receptors that typically bind multiple ligands and pro-
mote the removal of non-self or altered-self targets. They
often function by mechanisms that include endocytosis,
phagocytosis, adhesion, and signaling that ultimately
lead to the elimination of degraded or harmful substances.
Based on this definition, nomenclature and classification
of these receptors into 10 classes were proposed. The
discussion and nomenclature recommendations described
in this report only refer to mammalian scavenger recep-
tors. The purpose of this article is to describe the proposed
mammalian nomenclature and classification developed
at the workshop and to solicit additional feedback
from the broader research community. The Journal
of Immunology, 2014, 192: 1997–2006.
S
cavenger receptor activity was first described by
Drs. Michael Brown and Joseph Goldstein when they
identified receptors in macrophages that endocytosed
and degraded modified (acetylated), but not native, low-density
lipoprotein (LDL) (1). Drs. Brown and Goldstein showed that
these acetylated LDL receptors (LDLRs) recognized a wide
variety of polyanionic ligands (2). Purification and cloning
of the corresponding receptor protein and cDNA (3, 4) was
soon followed by the identification of other modified LDLRs
with broad binding specificity. In an initial attempt to sys-
tematically categorize these receptors, Dr. Monty Krieger
proposed to subdivide them into “classes” (A, B, and so forth)
based on their sequences, and each class was subdivided further
into “types” based on additional variations in their sequences
due to alternative splicing (5).
There are currently eight classes of scavenger receptors
(classes A–H). In some cases multiple names have been as-
signed to the same receptor (e.g., MSR1, SR-AI, CD204,
SCARA1). Additionally, there are proteins exhibiting scav-
enger receptor activity that have been named based on other
criteria and have not been included in a general scavenger re-
ceptor nomenclature. Some examples include receptor for ad-
vanced glycation end products (RAGE), LRP1, LRP2, ASGP,
CD163, scavenger receptor that binds phosphatidylserine and
oxidized lipids (SR-PSOX), and CXCL16. New scavenger re-
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ceptors also continue to be discovered and identified (6, 7).
Therefore, it is important to convey consistent understanding
and minimize redundancy and miscommunication in the scav-
enger receptor field. Developing a standardized nomenclature
has the benefit of decreasing redundancy and facilitating com-
munication and collaboration among investigators within a
field, as well as in different fields, by building on a common
understanding. Efforts to standardize other scientific nomen-
clatures have occurred in areas such as chemokines and their
receptors (8), the TNF family of receptors involved in bone
metabolism (9), complement peptide receptors (10), and glu-
tamate receptors (11). Committees formed specifically for
these processes by scientific societies or investigators in the
field have developed systematic nomenclatures within each
field for adoption by the broader scientific community.
To address the lack of a unified nomenclature system for
scavenger receptors and better organize the field, the U.S.
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, represented by Dr. Mercy PrabhuDas, ini-
tiated discussions with Dr. Joseph El Khoury and Prof. Siamon
Gordon, which led to organizing and convening a workshop in
which 15 investigators from five countries proposed a consensus
definition of scavenger receptors and a systematic, standard
nomenclature. We regret that Prof. Gordon was unable to
participate in the workshop due to prior commitments. The
workshop participants and their areas of expertise are listed
in Table I.
The objectives of this workshop were to: 1) establish guide-
lines and recommendations for standardizing the nomenclature
for scavenger receptors; 2) consider strategies for dealing with
future discoveries of scavenger receptors; and 3) communicate
the recommendations to the wider scientific community as a
point of reference and for further discussion and final scavenger
receptor nomenclature standardization. The discussion and
nomenclature recommendations described in this report only
refer to mammalian scavenger receptors.
Scavenger receptor background and history
The original description of scavenger receptors was in the
context of studies of lipoproteins, atherosclerosis, and familial
hypercholesterolemia (1, 12). Drs. Michael Brown and Joseph
Goldstein had previously identified LDLRs and LDLR-
mediated endocytosis and established that familial hypercho-
lesterolemia was caused by loss of function mutations in the
LDLR, which led to increased plasma LDL, premature athero-
sclerosis, and heart disease. Analysis of familial hypercholes-
terolemia patients showed that plasma LDL could also be
partially cleared by an LDLR-independent pathway called the
“scavenger pathway.” The earliest use of the term “scavenger
receptor” to refer to the broad specificity receptor identified by
Drs. Brown and Goldstein was in 1981 by Dr. Alan Fogelman
and colleagues (13).
The first scavenger receptors were purified in 1988 (14) and
cloned in 1990 (15, 16) by Dr. Monty Krieger’s group. These
receptors initially were named type I and type II macrophage
scavenger receptors and were found to be alternatively spliced
products of a single gene. When additional scavenger recep-
tors were identified, the type I and II macrophage receptors
were renamed scavenger receptor, class A, type I and type II
(SR-AI and SR-AII) by Dr. Krieger’s group. One distinct
feature of the broad binding specificity of scavenger receptors
was that they could recognize a large repertoire of ligands,
ranging from bacteria and yeast to self (native proteins) and
modified-self targets (2, 17–21). Besides playing a role in host
defense, class A scavenger receptors were shown to be in-
volved in functions such as homeostasis, Ag presentation, and
pathogenesis of neurodegenerative disorders (22, 23).
Based on their broad ligand-binding specificities and ex-
pression in macrophages, Dr. Krieger and colleagues proposed
that scavenger receptors could serve as pattern recognition
receptors for innate immunity (5). Work done by groups
led by Drs. Siamon Gordon, Tatsuhiko Kodama, and Joseph
El Khoury provided direct evidence that the class A receptors
are adhesion receptors, and that they recognize Gram-positive
bacteria and b-amyloid, confirming the broad ligand specificity
Table I. Workshop participants and their areas of expertise
Participant Affiliation Area of Expertise
Dawn Bowdish McMaster University, Hamilton, ON, Canada Macrophage scavenger receptors in host defense
Kurt Drickamer Imperial College, London, U.K. C-type lectin and glycan recognition
Joseph El Khoury Massachusetts General Hospital, Harvard Medical School,
Boston, MA
Macrophage and microglial scavenger receptors
in inflammation
Maria Febbraio University of Alberta, Edmonton, AB, Canada CD36 signaling
Joachim Herz University of Texas Southwestern Medical Center, Dallas, TX Functions of LDL receptor-related proteins
Lester Kobzik Harvard School of Public Health, Boston, MA MARCO and lung inflammation
Monty Krieger Massachusetts Institute of Technology, Cambridge, MA Scavenger receptors in host defense and lipoprotein
and lipid metabolism
John Loike Columbia University, New York, NY Scavenger receptors in neuropathology
Terry Means Massachusetts General Hospital, Harvard Medical School,
Boston, MA
Scavenger receptors and antifungal immune mechanisms
Soren Moestrup Aarhus University, Aarhus, Denmark Hemoglobin scavenger receptor
Philip Murphy National Institute of Allergy and Infectious Diseases,
National Institutes of Health, Bethesda, MD
G protein–coupled receptors in leukocyte trafficking
Steven Post University of Arkansas for Medical Sciences, Little Rock, AR Scavenger receptor A and atherosclerosis
Tatsuya Sawamura National Cerebral and Cardiovascular Center, Osaka, Japan Oxidized LDL receptor (LOX-1) and vascular
inflammation
Samuel Silverstein Columbia University, New York, NY Roles of scavenger receptors on mononuclear
phagocytes in chronic inflammatory diseases
Xiang-Yang Wang Virginia Commonwealth University, Richmond, VA Scavenger receptors in immune modulation
and host response














for these receptors (24, 25). Additional members of the class A
scavenger receptors such as macrophage receptor with collage-
nous structure (MARCO) (26) and SCARA5 (27) were sub-
sequently identified and shown to be involved in host defense.
Since the first discovery of the class A scavenger receptors, other
multiligand pattern recognition receptors were independently iden-
tified, including CD14 (28), mannose receptors (29), and CD36
(30). There are currently eight classes of scavenger receptors, and
summaries of each class of scavenger receptors are included
under the proposed nomenclature recommendations below.
Scavenger receptor nomenclature recommendations
Prior to initiating a discussion about nomenclature, the work-
shop participants developed a definition of scavenger receptors,
incorporating the various facets and characteristics of these
receptors. This definition was used as the benchmark against
which proposed nomenclatures were considered. As mentioned
above, scavenger receptors were originally defined as cell surface
proteins that bound chemically modified lipoproteins with
high affinity. Additional characteristics included the ability
to bind multiple ligands (broad-binding specificity), mediate
endocytosis, in some cases mediate signaling, and act as innate
immune pattern recognition receptors. Based on the dis-
cussion, the group agreed on the following working definition:
Scavenger receptors are cell surface receptors that typically bind
multiple ligands and promote the removal of non-self or altered
self targets. They often function by mechanisms that include en-
docytosis, phagocytosis, adhesion, and signaling that ultimately lead
to the elimination of degraded or harmful substances.
Fig. 1 illustrates the consensus nomenclature formula agreed
on at the meeting. As an example, a scavenger receptor be-
longing to class A would be designated as SR-A1, where SR
stands for scavenger receptor and is followed by a hyphen,
then a capital letter representing the class of SR, and then an
Arabic numeral representing the type of molecule within the
class. Alternate splice variants are designated by a dot and an
Arabic numeral following the type of molecule within the class
(e.g., SR-A1.1). The numbering is based on the order in
which the molecules were identified. Tables II and III provide
the current and proposed nomenclature for human and mouse
scavenger receptors. The following sections provide a brief
overview of the currently known scavenger receptor classes and
the proposed nomenclature for each class and member, as
recommended by the workshop participants.
Class A scavenger receptors: SR-A. Class A scavenger receptors are
expressed primarily on tissue macrophages and macrophage
subtypes such as Kupffer cells and cortical and medullary thymic
macrophages (31). They have also been observed on high
endothelial venules (31) and on subpopulations of dendritic
cells (32), binding to a variety of foreign and self ligands.
Members in this class have a similar structure, comprised of a
cytoplasmic tail, transmembrane domain, spacer region, a helical
coiled coil domain, collagenous domain, and a C-terminal
cysteine-rich domain. SCARA1/MSR1, the prototypical SR-A
molecule, was the first scavenger receptor to be cloned and was
initially isolated from bovine lung mRNA. It has subsequently
been identified in other species, including mice and humans.
There are three isoforms, identified as alternative splice variants
encoded by the same gene, namely, SR-AI, SR-AII, and
SR-AIII (33, 34). Other members of this class of scavenger
receptors include MARCO, SCARA5, and scavenger receptor
with C-type lectin domain (SRCL)-I/II, also designated col-
lectin from placenta receptor-I (35).
The scavenger receptor currently designated as SCARA1 or
MSR1 would now be referred to as SR-A1. SR-A1 is predom-
inantly found in macrophages, monocytes, mast cells, and
dendritic cells in both mice and humans (36). A diverse array
of ligands is recognized by members of this class. SR-A1
binds to b-amyloid, heat shock proteins, surface molecules
of Gram-positive and Gram-negative bacteria, hepatitis C
virus (34), and modified LDL such as acetylated LDL and
oxidized LDL (oxLDL), but not native LDL.
SR-A1.1, an alternatively spliced form of SR-A1 (currently
referred to as SR-AII), is characterized by a shortened C ter-
minus. SR-A1.2, another alternatively spliced form of SR-A1
(currently referred to as SR-AIII), is characterized by a trun-
cated C terminus and remains trapped in the endoplasmic
reticulum. The collagenous region of SR-A1 and SR-A1.1 has
been identified as a ligand-binding domain (37). There would
be no receptor designated as SR-A2 to avoid confusion with
the current SR-AII (new designation of SR-A1.1)
Whereas SR-A1 and SR-A6 (currently known as MARCO)
are primarily expressed in macrophages, SR-A3 (also referred
to as SCARA3, cellular stress response [CSR]), SR-A4 (SCARA4,
SRCL, collectin placenta 1 [CL-P1]), and SR-A5 (SCARA5) are
expressed in a variety of other tissues and cell types, including
the lung, placenta, intestine, heart, and epithelial cells (38). SR-
A3 has been associated with protecting cells from the detri-
mental effects of reactive oxygen species (21). SR-A4 functions as
an endocytic receptor for lipoproteins and mediates the rec-
ognition, internalization, and degradation of oxidatively mod-
ified LDL by vascular endothelial cells (39). SR-A5 (currently
known as SCARA5) expression is restricted to epithelial cells
within the testis, airway, thymus, and the adrenal gland. SR-A5
has the capacity to bind bacteria and may play an important
role in host defense (27). Under normal conditions, in the
absence of inflammation, the expression of SR-A6 is restricted
to macrophages in the lymph nodes and marginal zone of the
spleen. Studies have shown that SR-A6 mediates the clearance
of bacteria from the lungs (40) and bloodstream (41).
Proposed member nomenclature
SR-A1: the protein currently known as MSR1, SCARA1
[prototype].
FIGURE 1. Proposed scavenger receptor nomenclature formula. Proposed no-
menclature formula: SR stands for scavenger receptor. SR is followed by a hyphen,
then a capital letter representing the class of SR (A–J) followed by an Arabic
numeral representing the type of molecule within the class (the numbering is based
on the order in which themolecules were identified). Alternatively spliced forms of
a molecule will be designated as 1.1, 1.2, and so forth. For existing spliced variants,
the longest variant in terms of amino acid sequence will be given the first number.














SR-A1.1: the protein currently known as SR-AII. This is an
alternatively spliced form of SR-A1.
SR-A1.2: the protein currently known as SR-AIII. This is also
an alternatively spliced form of SR-A1.
There would be no receptor designated as SR-A2. This excep-
tion was agreed on during the meeting to avoid confusion with
the current SR-AII, which would now be designated as SR-A1.1.
SR-A3: the protein currently known as MSRL1 or APC7; the
current gene name is SCARA3.
SR-A4: the protein currently referred to as scavenger receptor
C-type lectin; the current gene name is SCARA4.
SR-A5: the protein currently known as TESR; the current gene
name is SCARA5.
SR-A6: currently named MARCO; the gene name is SCARA2.
The workshop participants recommended that the gene name
be changed to SCARA6 for consistency.
Class B scavenger receptors: SR-B. Class B scavenger receptors
include receptors currently known as SR-BI, SR-BII, CD36,
and LIMP2. Receptors belonging to this class are characterized
by two transmembrane domains flanking an extracellular loop,
with both the amino and carboxyl termini located within
the cytoplasm. The extracellular domain of these receptors
is extensively N-linked glycosylated, and this modification
provides protection against proteases often found in inflam-
matory sites. CD36 is the prototype class B type I scavenger
receptor and was initially identified as a receptor for throm-
bospondin (42), and in this capacity it modulates angiogenesis
and cell-to-cell interactions. It is one of the most widely
studied scavenger receptors and is involved in multiple aspects
of macrophage biology, including migration and signaling and
inflammatory processes such as foam cell formation. CD36
also plays an important role in the host immune response to
fungi and bacteria and binds erythrocytes infected with the
malaria parasite Plasmodium falciparum (43), as well as func-
tions as a facilitator of long chain fatty acid uptake (44). It is
expressed in many cell types, including insulin-responsive cells;
hematopoietic cells such as platelets, monocytes, and macro-
phages; and endothelial cells and specialized epithelial cells in
the breast and eye. Dr. Gerda Endemann and colleagues were
the first to characterize CD36 as a receptor for oxLDL, thereby
cementing its role as a scavenger receptor (30). CD36 also binds
polyanionic ligands of both host (e.g., high-density lipoprotein
[HDL]) (45) and pathogen (examples are Staphylococcus aureus
and Candida albicans) (20, 46) origin, and it plays an im-
portant role in the recognition and endocytic uptake of
oxidized phospholipids, apoptotic cells, and amyloid proteins
Table II. Summary of current mouse scavenger receptor nomenclature and proposed changes





MSR1 SR-A1, SCARA1 SR-A1 NM_031195 20288 8
Alternatively spliced
form of SR-A1
SR-AII SR-A1.1 —b —b 8
MARCO SCARA2, Ly112 SR-A6 NM_010766 17167 1
SCARA3 MSRL1, APC7 SR-A3 NM_172604 219151 14
COLEC12 SCARA4, SRCL, CL-P1 SR-A4 NM_130449 140792 18
SCARA5 TESR SR-A5 NM_028903 71145 14
CD36 SCARB3, PAS4 SR-B2 NM_001159558 12491 5
SCARB1 SR-B1, CD36L1 SR-B1 NM_016741 20778 5
Alternatively spliced
form of SR-B1
SR-BII SR-B1.1 —b —b 5
SCARB2 LIMP2, CD26L2, LGP85 SR-B3 NM_007644 12492 5
CD68 gp110, SCARD1, Macrosialin SR-D1 NM_009853 12514 11
OLR1 LOX-1, SCARE1 SR-EI NM_138648 108078 6
Alternatively spliced
form of SR-E1
LOXIN SR-E1.1 —b —b 6
CLEC7A DECTIN-1 SR-E2 NM_020008 56644 6
SCARF1 SREC-1 SR-F1 NM_001004157 380713 11
SCARF2 SREC-II SR-F2 NM_153790 224024 16
MEGF10 GM331 SR-F3 NM_1001979 70417 18
CXCL16 SR-PSOX SR-G NM_023158 66102 11
STAB1 FEEL-1 SR-H1 NM_138672 192187 14
STAB2 FEEL-2 SR-H2 NM_138673 192188 10
CD163 (M130) SR-I1 NM_053094 93671 6
CD163L1 SCART1 SR-I2 NM_172909 244233 7
SRCRB4D S4D-SRCRB To be named NM_001160366 109267 5
SSC5D S5D-SRCRB To be named NM_173008 269855 7
Fcrls IgSR, MSR To be named NM_030707 80891 3
CD14 None known To be named NM_009841 12475 18
Ly75 CD205, DEC-205 To be named NM_013825 17076 2
MRC1 CD206, MR To be named NM_008625 17533 2
CD207 Langerin To be named NM_144943 246278 6
CD209a DC-SIGN, CLEC4L To be named NM_133238 170786 8
LRP1 CD91, ASGPR To be named NM_008512 16971 10
RAGE (membrane form) AGER SR-J1 NM_007425 11596 17
RAGE (soluble form) AGER (soluble) SR-J1.1 AB207883 11596 17
aScavenger receptors that are designated “To be named” were not discussed at the workshop and will require additional input from the scientific
community.
bNational Center for Biotechnology Information reference sequence numbers are not available for the alternatively spliced forms of these receptors at this time.
NCBI, National Center for Biotechnology Information.














(47). Dr. Cameron Stewart and colleagues have shown that
CD36 (SR-B2) cooperates with TLR family members (TLR4
and TLR6) to activate the innate immune response to ligands that
accumulate in Alzheimer’s disease and atherosclerosis, inducing
proinflammatory mediators such as IL-1b and RANTES.
SR-B1 (also known as SCARB1 or SR-BI) was the first HDL
receptor to be identified and mediates the selective transport of
lipids, such as cholesteryl esters from HDL, from lipoproteins
to cells (48, 49). SR-B1 is most highly expressed by hepa-
tocytes and steroidogenic cells and is also found in cells within
the arterial wall and macrophages in human and murine ath-
erosclerotic lesions (50). SR-B1 has been shown to have a
protective effect on atherosclerosis development; total body
ablation of SR-B1 in apolipoprotein E knockout mice fed a
normal chow diet led to severe coronary arterial atheroscle-
rosis, myocardial infarction, and death (51). Ablation of
SR-B1 in bone marrow cells of LDL receptor knockout mice
also resulted in increased atherosclerosis, but not death, in-
dicative of partial protection against atherosclerosis (52).
SR-BII, an alternatively spliced form of SR-BI, contains a
distinctly different cytoplasmic tail than SR-BI. SR-BII is ex-
pressed in adrenal glands, testes, and liver, and it has been
shown to mediate selective uptake of cholesteryl ester from
HDL, with ∼4-fold lower efficiency than SR-BI (53).
One other member of the CD36 family of membrane
proteins, LIMP2 (SR-B3), functions primarily in delivering
b-glucocerebrosidase from the endoplasmic reticulum to lyso-
somes. SR-B3 has been identified as a cellular receptor for
enterovirus 71 (EV71), coxsackievirus 7 (CVA7), CVA14, and
CVA16 entry into host cells. SR-B3 also serves a role in viral
uncoating, thereby increasing infection efficiency (21). Expression
of SR-B3 on the cell membrane has not been confirmed.
Proposed member nomenclature
SR-B1: originally cloned as the HDL receptor, the gene name is
SCARB1; protein is currently also known as SR-BI.
SR-B1.1: an alternatively spliced form of SR-B1, currently known
as SR-BII.
SR-B2: the protein currently known as CD36 [prototype].
SR-B3: the protein currently known as LIMP2.
Class C scavenger receptors.Class C scavenger receptors have been
described in Drosophila (5), but there are currently no known
mammalian class C scavenger receptors. This scavenger recep-
tor class was not discussed because the workshop participants
focused on mammalian scavenger receptors.
Class D scavenger receptors: SR-D. CD68 is the only known mem-
ber of the class D scavenger receptors. CD68, also known as
macrosialin in mice, is a type I transmembrane glycoprotein that
belongs to the lysosome-associated membrane protein family of
molecules (54). There is a 300-aa extracellular region that is rich
in threonine and serine, which may serve as an attachment
site for carbohydrates, and a short cytoplasmic tail. Human
CD68 shares 75% amino acid sequence identity to mouse
CD68 in the extracellular region. CD68 is found on mono-
cytes and tissue-specific macrophages in the peritoneum, lungs,
liver, spleen, Langerhans cells, and microglia, and it serves
as a scavenger receptor for oxLDL. CD68 is a differentiation
Table III. Summary of current human scavenger receptor nomenclature and proposed changes





MSR1 SR-A1, CD204, SCARA1 SR-A1 NM_138715 4481 8
Alternatively spliced
form of SR-A1
SR-AIII SR-A1.2 NM_138716 4481 8
MARCO SCARA2 SR-A6 NM_006770 8685 2
SCARA3 MSRL1 SR-A3 NM_016240 51435 8
COLEC12 SCARA4, SRCL, CL-P1 SR-A4 NM_130386 81035 18
SCARA5 TESR, NET33 SR-A5 NM_173833 286133 8
CD36 SCARB3, FAT, GPIV, PAS4 SR-B2 NM_001001548 948 7
SCARB1 SR-BI, CD36L1 SR-B1 NM_005505 949 12
SCARB2 LIMP2, CD36L2, LGP85 SR-B1.1 NM_005506 950 4
CD68 gp110, SCARD1, LAMP4 SR-D1 NM_001251 968 17
OLR1 LOX-1, SCARE1, CLEC8A SR-E1 NM_002543 4973 12
Dectin 1 CLEC7A SR-E2 NM_197947 64581 12
SCARF1 SREC-1 SR-F1 NM_003693 8578 17
SCARF2 SREC-II SR-F2 NM_153334 91179 22
MEGF10 EMARDD SR-F3 NM_032446 84466 5
CXCL16 SR-PSOX SR-G NM_001100812 58191 17
STAB1 FEEL-1 SR-H1 NM_015136 608560 3
STAB2 FEEL-2 SR-H2 NM_017564 55576 12
CD163 M130 SR-I1 NM_004244 9332 12
CD163L1 M160, CD163B SR-I2 NM_174941 283316 12
SRCRB4D S4D-SRCRB To be named NM_080744 136853 7
SSC5D None known To be named NM_001144950 284297 19
CD14 None known To be named NM_000591 929 5
CD205 Ly75 To be named NM_002349 4065 2
CD206 MRC1 To be named NM_002438 4360 10
CD207 Langerin To be named NM_015717 50489 2
CD209\DC-SIGN CLEC4L To be named NM_021155 30835 19
RAGE (membrane form) AGER SR-J1 NM_001136 177 6
RAGE (soluble form) AGER SR-J1.1 AB061668 177 6
aScavenger receptors that are designated “To be named” were not discussed at the workshop and will require additional input from the scientific
community.
NCBI, National Center for Biotechnology Information.














marker of hematopoietic cells of the monocyte/macrophage
lineage. It is mostly found in the late endosomal compartment
in macrophages and dendritic cells, with limited expression on
resting cells. CD68 plays a minor role in the binding and
uptake of oxidized lipoproteins and apoptotic cells by macro-
phages (23). The proposed new nomenclature for this molecule
is: SR-D1: currently known as CD68 [prototype].
Class E scavenger receptors: SR-E. Class E scavenger receptors are
type 2 transmembrane proteins with C-type lectin-like do-
mains and demonstrated scavenger receptor activity; sequence
homology alone is not sufficient to include a protein in this
class of receptors. These proteins structurally belong to a sub-
family of the C-type lectin (CLEC)–like NK cell receptor family.
The NK receptor gene complex encodes a large number of
CLEC-like receptors that are expressed on NK cells and other
leukocytes. Analysis of the NK receptor gene complex in five
species revealed variations in the sizes of gene clusters in each
species that ranged from 22 to 75 clusters and are noted in
these species: human (29 clusters), dog (22 clusters), cattle
(32 clusters), rat (75 clusters), and mouse (57 clusters) (55).
Among these gene clusters, the first two members of the CLEC
family, lectin-like oxLDL receptor (LOX-1) and Dectin-1, have
been well characterized and shown to have scavenger activity.
LOX-1 is expressed on macrophages and dendritic cells and
binds oxidized LDL and the acute phase protein C-reactive
protein (56). It was originally cloned from a bovine aortic
endothelial cDNA expression library screened for receptors
for oxidized LDL (57). LOX-1 is expressed on vascular endo-
thelial cells, platelets, smooth muscle cells, adipocytes, and mac-
rophages. In addition to binding oxidized LDL, LOX-1 has been
implicated in recognizing other ligands, including apoptotic cells,
Gram-positive bacteria, and Gram-negative bacteria (23, 56).
A splicing variant of human LOX-1 lacking a lectin-like do-
main, called LOXIN, works as a dominant-negative isoform,
forming a heterodimeric complex with LOX-1 (58).
Dectin-1 is expressed predominantly on myeloid cells (mac-
rophages, dendritic cells, and neutrophils) and can be regulated
by cytokines and microbial stimuli. Human Dectin-1 is alter-
natively spliced, resulting in two functional forms. This receptor
recognizes various bacterial, fungal, and plant carbohydrates
(b-1,3- and/or b-1/6-glucans) in addition to intact fungi
and parasites (59). Dectin-1 mediates proinflammatory cytokine
production in response to b-glucan particles, in conjunction
with TLR2. It can also function as a phagocytic receptor
through a novel Syk-independent pathway. Dectin-1 has
been reported to act as a costimulatory molecule to activate
both CD4 and CD8 T cells. Moreover, Dectin-1 is expressed
on macrophages and dendritic cells in the medullary regions
of the thymus, suggesting a role in thymocyte development
(60).
Some CLEC family members are known to recognize
pathogen-associated molecules. However, most of the members
of the CLEC family have not been shown to have scavenger
receptor activity. At this time, only LOX-1 andDectin-1 would
be classified as scavenger receptors using the definition proposed
by the workshop participants.
Proposed member nomenclature
SR-E1: the protein currently known as LOX1. Gene name OLR1
[prototype].
SR-E1.1: alternatively spliced form of SR-E1 also known as
LOXIN (no known scavenger receptor activity but works as a
dominant-negative form).
SR-E2: the protein currently known as Dectin-1.
Class F scavenger receptors: SR-F. There are currently three mem-
bers belonging to the class F scavenger receptors. The first
class F scavenger receptor (SCARF1) was identified as an en-
dothelial receptor for modified LDL and is characterized by
the presence of an extracellular ligand-binding domain, with
multiple extracellular epidermal growth factor–like repeats,
a transmembrane domain, and a long cytoplasmic tail that
includes a serine/proline-rich region followed by a glycine-
rich region. It was named scavenger receptor expressed by
endothelial cells (SREC)-I (61) and later was also named
SCARF1. SCARF1/SREC-I is also expressed in macrophages
and functions to bind calreticulin and associated peptides,
which are transported into the MHC class I pathway in mac-
rophages and dendritic cells (23). SCARF1 also was shown to
be a receptor for fungal pathogens and heat shock proteins
(20, 34). Interestingly, a Caenorhabditis elegans ortholog of
SCARF1, CED-1, plays a role in engulfing apoptotic cells
and has been implicated in host defense (23). A recent report
indicates that SCARF1, similar to CED-1, is also involved in
the clearance of apoptotic cells (62).
A second isoform of SREC-I, SREC-II, was cloned by
Dr. Hiroyuki Arai’s group (63) and was shown to be pre-
dominantly expressed in heart, placenta, lung, kidney, spleen,
small intestine, and ovary. SREC-II is a type I transmembrane
receptor containing N-terminal epidermal growth factor–like
domains, a transmembrane domain, and a long cytoplasmic
tail, and it engages in heterophilic interactions with SREC-I.
In contrast to SREC-I that binds and internalizes modified
LDL, SREC-II is unable to internalize modified LDL. The
cytoplasmic domain of SREC-II is rich in arginine and lysine,
whereas SREC-I is rich in serine and proline. The significance
of these residues is not known at this time.
Another member of the SCARF family, multiple epidermal
growth factor (EGF)–like domains (MEGF)10, recently has
been shown to be a receptor for the protein amyloid-b in the
brain, and it is thought to be involved in the pathogenesis of
Alzheimer’s disease (23). It is not clear yet whether other
MEGF family members, such as MEGF8, 9, and 11, also have
scavenger receptor function because no functional studies have
been published to date on these molecules.
Proposed member nomenclature
SR-F1: the protein currently known as SREC-I/SCARF1
[prototype].
SR-F2: the protein currently known as SREC-II/SCARF2.
SR-F3: the protein currently known as MEGF10.
Class G scavenger receptors: SR-G. Currently, one receptor belongs
to scavenger receptor class G, SR-PSOX/CXCL16. Dr. Takeshi
Shimaoka and colleagues used expression cloning of a cDNA
library from PMA-treated human monocytic THP-1 cells to
identify scavenger receptors that bound oxLDL, and they
discovered this receptor, which they called SR-PSOX (64). At
about the same time, Drs. Jason Cyster and Michael Briskin
discovered a new chemokine that was capable of activating
the receptor, CXCR6 (also known as BONZO, STRL33 or
TYMSTR), resulting in migration of T cells in vitro (65–67).














This chemokine was named CXCL16 and was found to be
identical to SR-PSOX in its amino acid sequence.
Studies show that the SR-PSOX/CXCL16 gene is located
on chromosome 17p13, and its protein exists in both mem-
brane and soluble forms (65). It is a type I transmembrane
glycoprotein with a CXC chemokine motif, mucin stalk, and
transmembrane and soluble domains. SR-PSOX/ CXCL16
does not share structural homology with other scavenger re-
ceptors. SR-PSOX/CXCL16 has the capacity to mediate
adhesion and phagocytosis of bacteria by APCs (66). The
membrane-bound form can function as an adhesion molecule
for CXCR6-expressing T cells without requiring CXCR6-
induced signal transduction and integrin activation.
This multifunctional transmembrane protein has a chemo-
kine-like CXC motif and appears to be involved in several
phases of an immune response, from Ag recognition to mi-
gration of immune cells to formation of inflammatory foci
(68). The soluble form of SR-PSOX/CXCL16, produced from
cleavage of the membrane-bound form, functions as a chemo-
attractant for activated T cells and bone marrow plasma cells
via its receptor CXCR6 (69). The membrane-bound form acts
as a scavenger receptor for oxLDL and facilitates phagocytosis
of bacteria by APCs (69).
Proposed member nomenclature
SR-G1: the protein currently known as SR-PSOX/CXCL16
[prototype].
Class H scavenger receptors: SR-H. Receptors in this class are
transmembrane proteins that consist of Fasciclin, EGF-like
and lamin type EGF-like (FEEL) domains. The currently
known SR-H members are FEEL-1/Stabilin-1/CLEVER-1
and FEEL-2/stabilin-2/HARE. FEEL-1 is predominantly ex-
pressed in macrophages, mononuclear cells, hematopoietic
stem cells, and endothelial cells, whereas FEEL-2 is found
mainly in sinusoidal endothelial cells. FEEL-1 and FEEL-2
have been shown to be involved in lymphocyte adhesion,
transmigration, angiogenesis, apoptotic cell clearance, and
intracellular trafficking. FEEL-1 and FEEL- 2 also have been
implicated in the clearance of aged RBCs by macrophages
(70, 71) in a phosphatidylserine-dependent manner. FEEL-1
has been shown to directly interact with and is sufficient for
phagocytosis of phosphatidylserine-coated beads. These results
have yet to be confirmed in vivo. However, FEEL-1 and
FEEL-2 double knockout mice have been shown to be impaired
in the clearance of noxious blood factors (72).
Proposed member nomenclature
SR-H1: the protein currently known as FEEL-1, Stabilin-1 and
CLEVER -1 [prototype].
SR-H2: the protein currently known as FEEL-2/Stabilin-2.
Class I scavenger receptors: SR-I.Members of the class I scavenger
receptors are primarily restricted to the monocytic lineage,
of which CD163, the prototypic class I scavenger receptor, is
expressed exclusively in monocytes and macrophages and binds
to haptoglobin/hemoglobin (Hgb) complexes to promote the
clearance of plasma Hgb via endocytosis during intravascular
hemolysis. CD163 is a type I transmembrane protein that
consists of an extracellular region composed of nine scavenger
receptor cysteine-rich (SRCR) domains and a short cyto-
plasmic tail. CD163 was originally cloned from the spleen
of a patient afflicted with hairy cell leukemia, characterized
by a large number of tissue macrophages. It is a 130-kDa
membrane glycoprotein, and was known as M130 prior to
being given a CD designation. CD163 was also given the
functional name “hemoglobin scavenger receptor” to describe
its primary role in tissue macrophages (73). Its role as an
Hgb receptor may contribute to enhancement of an anti-
inflammatory response because the proinflammatory heme is
converted to anti-inflammatory metabolites (74).
In addition to functioning as an Hgb receptor, CD163
appears to be involved in intracellular signaling, resulting in
a protein-kinase–dependent signal and secretion of cytokines
such as IL-6 and IL-10 (75). Several CD163 mRNAs arising
from an alternatively spliced CD163 gene have been reported
(73, 75). Confocal microscopy studies revealed that the shortest
tail variant is predominantly present in the cell membrane,
whereas the longer variants are located in the endosomal/Golgi
cellular compartment (75). One short tail variant and two
long tail variants have been shown to bind and internalize
haptoglobin/Hgb complexes leading to lysosomal degradation
of the complex. The short tail variant is the predominant iso-
form found in human blood, liver, and spleen, and most of the
long tail variants appear in endosomal compartments (75).
CD163-L1 (M160), a long tail variant of CD163, is a type I
transmembrane molecule structurally composed of scavenger
receptor cysteine-rich domains, expressed by cells of the myeloid
lineage, and may be involved in the differentiation of mono-
cytes to macrophages. Two cytoplasmic splice variants of
CD163-L1 have been identified thus far; these include the
full-length variant (CD163L1a) with a cytoplasmic tail of
71 residues and the short tail variant (CD163-L1b) with
39 residues. CD163-L1a is the predominant membrane-
associated form in several human tissues such as spleen, pla-
cental, and small intestine, whereas CD163-Lb is mainly
found in intracellular compartments (76). Studies to iden-
tify endogenous and microbial ligands of CD163-L1b are
currently in progress.
Proposed member nomenclature
SR-I1: the protein currently known as CD163, M130 [prototype].
SR-I1.1: the CD163 long tail variant 1.
SR-I1.2: the CD163 long tail variant 2.
SR-I2: currently known as CD163B, M160.
Class J scavenger receptors: SR-J. RAGE is currently the only mem-
ber of the class J scavenger receptor group, and it is a member
of the Ig superfamily of cell surface molecules capable of in-
teracting with a broad spectrum of ligands, including advanced
glycation end products, high mobility group protein box 1,
and the S-100 protein. RAGE is composed of a single trans-
membrane domain that connects the ectodomain with a short
cytoplasmic domain and an extracellular domain required for
ligand recognition and binding. The extracellular domain
comprises an N-terminal sequence and three Ig-like regions.
RAGE is a pattern recognition receptor predominantly in-
volved in the recognition of endogenous molecules released in
the context of infection, physiological stress, or chronic in-
flammation (77). Signaling through RAGE mediates processes
such as inflammation, oxidative stress, and apoptosis, which
can lead to pathologies including atherosclerosis, diabetes,
cancer, neurodegenerative disease, and stroke. RAGE signaling














also mediates normal neuronal processes such as cell migration
and neuronal differentiation. Studies assessing brain pathology
in Alzheimer’s disease revealed that diseased brains expressed
higher levels of RAGE in the vasculature and on neurons
compared with normal brains (23). In addition to a membrane-
bound form, a circulating portion of the protein known as
“soluble” RAGE also has biological properties.
Proposed member nomenclature
SR-J1: the protein currently known as the membrane-bound
form of RAGE/AGER [prototype].
SR-J1.1: the soluble form of RAGE.
Other potential scavenger receptors: SR-Others. The SR-Others
group refers to molecules with scavenger activity that do not
belong to the current SR classes, but belong to other receptor
families. These receptors include LDL receptor family proteins
such as LRP1, LRP2/megalin, cubam (the cubilin/amnionless
complex), ASGP, MR, and CD11b/CD18a. Classifying
these receptors as scavenger receptors will require the input of
the wider scientific community.
Conclusions
In addition to their functions as phagocytic receptors and
innate immune recognition receptors, scavenger receptors
also play an important role as regulators of inflammatory
signaling. These receptors have been implicated in a number
of physiological and pathological processes, including inter-
actions with other innate immune receptors, delivery of ligands
to different cellular compartments, and Ag presentation. Fur-
thermore, the roles of these receptors in neurodegenerative
diseases, diabetes, and other metabolic disorders, as well as
their potential as targets for therapeutic interventions to treat
various disorders, warrant further study. Having a standardized
nomenclature as described in this report would help to over-
come current ambiguities in communication about specific
scavenger receptors and, perhaps, remove a major barrier for
researchers in other fields to enter the scavenger receptor field.
This report serves as an initial step in presenting the pro-
posed nomenclature to the research community. A Web site
has been established to invite comments from fellow investi-
gators in response to the proposed nomenclature. The Web
site is https://respond.niaid.nih.gov/ScavengerReceptors/, which
will be open for public comment from March 1 through
July 31, 2014. Additionally, the National Institute of Allergy
and Infectious Diseases is organizing several discussion sessions
at the following upcoming national meetings: Experimental
Biology 2014 (April 29, 2014; http://experimentalbiology.org/
2014/Home.aspx) in San Diego, CA; IMMUNOLOGY 2014
in Pittsburgh, PA (May 4, 2014; http://www.immunology2014.
org/); and FOCIS 2014 (June 25, 2014; http://www.focisnet.
org/focis-2014) in Chicago, IL. These sessions will be open to
the meeting attendees to provide the broader scientific com-
munity with the opportunity to offer their comments and
recommendations on the proposed scavenger receptor no-
menclature. The National Institute of Allergy and Infectious
Diseases plans to publish the final nomenclature recommen-
dations in a subsequent publication in The Journal of Im-
munology, based on the comments received at these meetings
and at the scavenger receptor nomenclature Web site. The
final nomenclature will also be communicated to the Inter-
national Union of Pharmacology to facilitate distribution
to scientists working in areas related to pharmacology and
biological target research.
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